Boston Scientific (NYSE:BSX): Q2 Non-GAAP EPS of $0.39 beats by $0.01; GAAP EPS of $0.11 misses by $0.14.
Revenue of $2.63B (+5.6% Y/Y) misses by $10M.
Wednesday, July 24, 2019
Alexion Pharmaceuticals EPS beats by $0.30, beats on revenue
Alexion Pharmaceuticals (NASDAQ:ALXN): Q2 Non-GAAP EPS of $2.64 beats by $0.30; GAAP EPS of $2.04 beats by $0.28.
Revenue of $1.2B (+14.3% Y/Y) beats by $20M.
Medicines EPS misses by $0.04
Medicines (NASDAQ:MDCO): Q2 Non-GAAP EPS of -$0.63 misses by $0.04; GAAP EPS of -$0.80 misses by $0.05.
Tenet to spin-off Conifer unit
After evaluating strategic alternatives, Tenet Healthcare (NYSE:THC) announces its plan for a tax-free spin-off of its Conifer business by Q2 2021.
Conifer provides revenue cycle management and population health management services to health systems, physicians and employer groups, managing more than 17M unique patient interactions and ~$25B in net patient revenue each year. In 2018, it generated $1.533B in revenue and $357M in non-GAAP EBITDA (+26% yoy).
Conifer CEO Stephen Mooney has stepped down. COO Kyle Burtnett has taken over on an interim basis.
THC hosted a conference call this morning at 7:30 am ET to discuss the spin-off.
Lonza Group reports 1H results
Lonza Group (OTCPK:LZAGF): 1H Non-GAAP EPS of CHF6.96; GAAP EPS of CHF5.26.
Revenue of CHF2.98B (+6.4% Y/Y)
GlaxoSmithKline Q1 top-line up 7%; 2019 guidance raised
GlaxoSmithKline (GSK) Q2 results (£): Revenues: 7,809M (+6.8%); Pharmaceuticals: 4,307M (+1.8%); Vaccines: 1,585M (+26.5%); Consumer Healthcare: 1,917M (+4.9%).
Key product sales: Shingrix: $386M (+131.1%); Ellipta: $557M (+9.4%); Bexsero: $156M (+25.8%); Nucala: $195M (+38.3%).
Net Income: 964M (+118.6%); EPS: 0.195 (+122.2%); Non-GAAP Net Income: 1,509M (+9.3%); Non-GAAP EPS: 0.305 (+10.7%); CF Ops: 1,389M (+2.0%).
2019 Guidance: Non-GAAP EPS to decline in the range of (3%) to (5%) from (5%) to (9%) at CER.
Allergan recalls implants and tissue expanders due to lymphoma risk
As a precaution, Allergan (NYSE:AGN) is voluntarily recalling its BIOCELL textured breast implants and tissue expanders worldwide in response to global safety information about the rare risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).
Effective immediately, healthcare providers should not implant the products. Distribution and sales will also cease.
Global regulators, including the FDA, have not recommended the removal or replacement of the products in asymptomatic patients.
The company says the recall does not affect its NATRELLE smooth or MICROCELL breast implants and tissue expanders.
Update: In a statement, the FDA indicated that it requested the recall of specific models of textured implants from the U.S. market due to the cancer risk. To date, there have been 573 cases of BIA-ALCL, including 33 deaths, reported globally. 481 of the cases are attributed to Allergan implants, including 12 deaths. The agency says its analysis showed that the risk of BIA-ALCL is six times greater with Allergan’s BIOCELL compared to other manufacturers. The FDA is considering additional actions including updated labeling, which could include a boxed warning, and a decision checklist to help patients assess the benefits and risks of receiving a breast implant.
Subscribe to:
Posts (Atom)